Angiotensin-converting enzyme inhibition-emerging pulmonary issues relating to cough.
Angiotensin-converting enzyme (ACE) inhibitors are viewed by many as important treatment options for both the management of hypertension and the provision of end-organ protection. ACE inhibitors have not been looked on as having any clearly recognizable direct pulmonary benefits; rather, their pulmonary effects have been felt to be a nuisance by virtue of their association with cough. ACE inhibitor-related cough is well characterized. What is less well appreciated is the relationship between sleep apnea, pneumonia, and ACE inhibitor-related cough. These new pulmonary observations in patients afflicted with an ACE inhibitor-related cough should revive interest in this bothersome side effect.
Sica
Domenic A
DA
Department of Medicine, Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298-0160, USA. dsica@hsc.vcu.edu
Brath
Lisa
L
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D003371:Cough / Q000139:chemically induced* / Q000503:physiopathology; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D008168:Lung / Q000187:drug effects*; D011014:Pneumonia / Q000517:prevention & control*; D012891:Sleep Apnea Syndromes / Q000503:physiopathology*
D000806:Angiotensin-Converting Enzyme Inhibitors